Analyst Price Target is $44.71
▼ -4.25% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $44.71, with a high forecast of $55.00 and a low forecast of $37.00. The average price target represents a -4.25% upside from the last price of $46.70.
Current Consensus is
The current consensus among 13 investment analysts is to hold stock in Genmab A/S. This rating has held steady since May 2020, when it changed from a Buy consensus rating.
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.